At the news
? NEUTRALIMPACT 3/10 144 filed Apr 7, 2026 at 16:26 ET
Fady Malik, an officer at Cytokinetics, filed a Form 144 to notify intent to sell 22,000 shares of common stock, valued at approximately $1.43 million, acquired through stock option exercises. The filing is a routine notice of planned sales under Rule 144, with no indication of immediate market impact or unusual activity.
- Fady Malik, an officer of Cytokinetics, filed Form 144 to sell up to 22,000 shares.
- The shares are to be sold on the NASDAQ, with an approximate value of $1.43 million based on current market prices.
- Shares were acquired through the exercise of stock options on March 9 and March 17, 2026, and will be sold for cash.
- This is an advance notice of intent to sell; actual sale may not occur immediately or at all.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access